The MK-677 water retention conversation

This is one of the most reliable early experiences in MK-677 use, so common that it has its own name in the communities that discuss this compound: MK bloat. It's not a myth. It's not in your head. The physiology behind it is well characterized, the contributing pathways are multiple, and understanding what's happening is important both for managing expectations and for understanding the broader metabolic picture of why this compound was more complicated than its early biomarker data suggested.

Start with growth hormone itself. GH has well-documented effects on fluid balance. One of the mechanisms runs through IGF-1: as IGF-1 rises — which it does, measurably and consistently, with MK-677 use — it increases renal tubular sodium reabsorption. More sodium retained means more water retained to maintain osmotic balance. This is the same mechanism behind the fluid retention seen with exogenous GH injections, and it's dose-dependent in both cases. Higher IGF-1, more sodium retention, more water. The effect is partially mediated by aldosterone pathways, and while it is not the same as aldosterone excess, the functional result — swelling, particularly in the extremities and face — is recognizable to anyone who has experienced either.

The ghrelin receptor activation adds another layer. Ghrelin itself influences the renin-angiotensin-aldosterone system, the hormonal cascade that governs blood pressure and fluid volume. Sustained GHS-R1a activation doesn't activate this system in the same direct way as the RAAS drugs cardiologists manage, but it nudges it in the direction of retention. The compound is not doing just one thing metabolically. It is activating a receptor whose ligand — ghrelin — evolved in part to signal energy scarcity and prepare the body to hold onto resources. That includes fluid.

This matters for interpreting body composition changes on MK-677, and the misinterpretation is common enough to be worth addressing directly. DEXA scans and bioelectrical impedance — the methods most people use to track lean mass — have limitations when fluid balance is changing. Bioelectrical impedance is particularly sensitive: water is conductive, and more intracellular and extracellular fluid will read as more lean mass on many devices. Someone gaining four pounds of water weight on MK-677 and measuring themselves with a home impedance scale may be told they've gained lean mass. They haven't, or not primarily. The composition of the gain is different from what the measurement implies. This is not a reason to dismiss body composition data entirely, but it is a reason to be careful about interpreting early changes and to wait for enough time — typically several months — before drawing conclusions, using a consistent measurement method under consistent conditions.

The timing of the retention matters too. MK-677 water retention is typically most pronounced in the first several weeks of use, as IGF-1 rises to its new steady state. Most people report that it moderates substantially — not always completely, but noticeably — after four to eight weeks, as the kidneys and the hormonal systems governing fluid balance adapt. This is consistent with what was observed in the Merck clinical trials, where fluid retention was a reported adverse effect but was characterized as manageable in most subjects over time. The elderly subjects in the frailty studies who already had compromised cardiac or renal function were the population for whom this was least manageable — which is one of the reasons the compound's safety profile was considered more concerning in that population.

The community has developed a set of practical approaches to MK-677 water retention, and while none of them have been studied in controlled trials in this context, the logic is mechanistically coherent. Lower doses — 10 mg rather than 25 mg — produce less IGF-1 elevation and correspondingly less fluid retention. Some people find that the retention is substantially reduced at 10 mg relative to 25 mg, with meaningful IGF-1 elevation still present. The dose-response curve is not linear for all effects. Sodium consciousness — not necessarily aggressive sodium restriction, but awareness of high-sodium foods during the adaptation period — reduces the substrate for the sodium-retention mechanism. Adequate hydration maintains renal blood flow and supports appropriate fluid handling. These are sensible adaptations, not workarounds for a problem that doesn't matter.

Evening dosing has become the community norm for several reasons including the appetite effect, but morning dosing is sometimes reported to produce less noticeable daytime water retention — potentially because the overnight sleep period allows some of the acute retention to equilibrate. Whether this is real pharmacologically or represents selection bias in who reports what is not established. Time-of-day effects on the fluid retention specifically are not well studied.

The insulin sensitivity question is where the water retention becomes a gateway to a more serious conversation. IGF-1 elevation — the same elevation that drives the fluid retention — also affects insulin signaling. IGF-1 and insulin share structural homology and compete at the insulin receptor. Elevated IGF-1 can reduce insulin receptor sensitivity through receptor competition and through downstream effects on glucose transporter expression. Sustained ghrelin receptor activation has its own independent effects on glucose handling. The MK-677 trials showed elevated fasting glucose and reduced insulin sensitivity in some subjects, most notably in the elderly population studied and in those with pre-existing metabolic vulnerabilities.

This is not the same as saying MK-677 causes diabetes. It is saying that the metabolic effects of this compound are real, are not benign in the aggregate, and are one of the reasons Merck was not able to build a clean safety profile for the indications they were pursuing. In a young, metabolically healthy person doing regular resistance training, the insulin sensitivity impact of MK-677 may be minor and reversible with modest lifestyle adjustment. In someone with impaired fasting glucose, insulin resistance, or a family history of type 2 diabetes, the picture is less comfortable. This is exactly the kind of individualized risk assessment that requires actual lab work — fasting glucose, insulin, HbA1c at baseline and during use — and a prescribing provider who can interpret the numbers in context.

The water retention is not the point. It is a signal pointing toward the metabolic complexity underneath. The same mechanism that produces the puffy face and the tight rings — sustained IGF-1 elevation, GHS-R1a activation, the downstream effects on aldosterone and sodium handling — is also the mechanism that raises questions about glucose. These are the same biology, not separate issues. Managing one by adjusting dose or watching sodium is reasonable. Managing the other requires clinical surveillance.

What water retention on MK-677 is telling you, at the most basic level, is that the compound is doing something physiologically real. IGF-1 is rising. The body is responding. Whether that response is net beneficial depends on factors you cannot assess by standing on a scale. The four pounds that showed up in the first three weeks is not the goal. It is the side effect of the goal, and the same mechanism is doing both.

There is also a question worth raising about what water retention means for the people who are using MK-677 specifically for body composition — which is a significant portion of the community. If the goal is lean mass gain, and the measurement tool is a home scale or a bioelectrical impedance device, the first month of MK-677 use produces data that is almost impossible to interpret cleanly. Weight is up. The impedance device says lean mass is up. The mirror says something is different, though it's hard to say if it's muscle or water. The honest answer is that at three weeks, four weeks, even eight weeks, it's largely both — and the proportions are genuinely difficult to disentangle without DEXA scanning at consistent conditions over a longer timeline. This measurement ambiguity has contributed to a persistent overestimation of MK-677's lean mass effects in community discussion. People attribute gains to the compound that are substantially water. Then when they stop and the water clears, they conclude the compound stopped working. Some of the cycling debates in forums are downstream of this measurement confusion as much as they are about actual biology.

The compound is not FDA-approved. The long-term metabolic consequences of sustained GHS-R1a activation in humans, over years, are not characterized by clinical data. The community that uses MK-677 has developed a reasonable working knowledge of the acute fluid retention. The glucose and insulin story is less consistently tracked and discussed, which is worth noting. Labs, not just scale weight, are the appropriate monitoring tool here — and that monitoring happens most safely with clinical oversight, not forum advice.